Bayer is a global life sciences leader in healthcare and nutrition. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing therapies and delivering first-in-class educational and support programs to meet their needs.

This information has been reviewed according to the US law and is consistent with US Prescribing Information and is intended for US audience only. Prescribing Information may vary depending on local approval in each country.

Click here to learn more about Xofigo (radium Ra 223 dichloride)

Click here to learn more about NUBEQA (darolutamide)


For additional information, contact:

Rebecca Cowens-Alvarado, MPH

Deputy Director Advocacy Relations

Email: Rebecca.cowens-Alvarado@bayer.com




EDUCATIONAL RESOURCES

Living With Cancer Website:

https://www.thisislivingwithcancer.com/living-with-app

Pfizer Virtual Booth:

http://pfizeroncologycongressresources.com

Living With Cancer iTunes App:

https://apps.apple.com/us/app/id1223073769

Know Your Prostate Plan – Patient Videos

https://www.knowyourprostateplan.com/patient-stories

Click here for Full Prescribing Information



CLICK HERE TO DOWNLOAD THE BROCHURE

PROSTOX genetic tests help prostate cancer patients choose the safest form of radiation treatment

These tests predict a patient’s risk of late, long-term side effects following two radiation treatment approaches for prostate cancer, based on the number of fractions a patient will receive:

  • PROSTOX ultra: for 5-7 fractions (sessions) given over 10 days, and called stereotactic body radiotherapy (SBRT)

  • PROSTOX CFRT: for 35-45 fractions (sessions) given over 8-10 weeks

Patient Information and Access

Find out if you’re eligible to access PROSTOX testing through MiraKind and learn more: https://mirakind.org/prostox-testing/

Clinical evidence and Information for physicians

https://miradx.com/prostox


Prolaris Explainer Video

Gary’s Prolaris Patient Testimonial



PAN FOUNDATION

We help underinsured people with life-threatening, chronic and rare diseases get the medications and treatments they need by assisting with their out-of-pocket costs and advocating for improved access and affordability.

RESOURCES: